ELPIS BIOPHARMACEUTICALS IS COMMITTED TO DEVELOPING NEXT GENERATION CELLULAR AND BIOLOGIC THERAPEUTICS FOR CANCER PATIENTS
Elpis has developed two core technology platforms: the mRNA Display & Selection technology with a proprietary highly diverse fully human antibody library (mADsTM) and the proprietary rational-designed library for scaffold protein of interest (mSCAFoldTM), respectively.
mADSTM enables rapid screening and discovery of highly selective and potent ScFv or VH domain antibody modules against therapeutic targets utilizing either soluble proteins or live cells for selection. Live cell selection is particularly valuable for generating antibodies binding to the disease relevant epitopes and challenging targets such as multi-transmembrane proteins. ScFv and VH domains can be further engineered to generate bispecific or multi-functional cellular or biologic modalities.
Taking advantage of our understanding of the structure-function relationship between a target of interest and its interaction partner(s), we rationally design tailored libraries. We then utilize mRNA display technology to screen and identify engineered mutants with re-directed pharmacological properties (e.g. agonist or antagonist) for therapeutic applications. Our technology platform enables rapid protein engineering leading to proteins with specific mechanisms of action.